Endocrine resistance in breast cancer--An overview and update.

@article{Clarke2015EndocrineRI,
  title={Endocrine resistance in breast cancer--An overview and update.},
  author={Robert Clarke and John J. Tyson and J Michael J Dixon},
  journal={Molecular and cellular endocrinology},
  year={2015},
  volume={418 Pt 3},
  pages={220-34}
}
Tumors that express detectable levels of the product of the ESR1 gene (estrogen receptor-α; ERα) represent the single largest molecular subtype of breast cancer. More women eventually die from ERα+ breast cancer than from either HER2+ disease (almost half of which also express ERα) and/or from triple negative breast cancer (ERα-negative, progesterone receptor-negative, and HER2-negative). Antiestrogens and aromatase inhibitors are largely indistinguishable from each other in their abilities to… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 3 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 45 extracted citations

Estrogen-regulated feedback loop limits the efficacy of estrogen receptor–targeted breast cancer therapy

Proceedings of the National Academy of Sciences of the United States of America • 2018
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 202 references

Pembrolizumab for the treatment of non-small cell lung cancer.

Expert opinion on biological therapy • 2016
View 1 Excerpt

A uhor M anscript A uhor M anscript A uhor M anscript A uhor M anscript

P Eirew, A Steif, +17 authors Clarke de
Mol Cell Endocrinol. Author manuscript; available in PMC 2016 December 15 • 2015
View 1 Excerpt

Accurate Prediction and Validation of Response to Endocrine Therapy in Breast Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2015
View 1 Excerpt

Similar Papers

Loading similar papers…